NCBI Logo
GEO Logo
   NCBI > GEO > Accession DisplayHelp Not logged in | LoginHelp
GEO help: Mouse over screen elements for information.
          Go
Series GSE227590 Query DataSets for GSE227590
Status Public on Aug 05, 2023
Title Genome-wide Translational Response of Candida albicans to Fluconazole Treatment
Organism Candida albicans
Experiment type Expression profiling by high throughput sequencing
Summary Azoles are commonly used for the treatment of fungal infections and the ability of human fungal pathogens to rapidly respond to azole treatment is critical for the development of antifungal resistance. While the role of genetic mutations, chromosomal rearrangements and transcriptional mechanisms in azole resistance has been well-characterized, very little is known about post-transcriptional and translation mechanisms that drive this process. In addition, most previous genome-wide studies have focused on transcriptional responses to azole treatment, and likely serve as an inaccurate proxies due to extensive post-transcriptional and translational regulation. In this study we use ribosome profiling to provide the first picture of the global translational response of a major human fungal pathogen, Candida albicans, to treatment with fluconazole, one of the most widely used azole drugs. We identify sets of genes showing significantly altered translational efficiency (TE), including genes associated with a variety of biological processes such as the cell cycle, DNA repair, cell wall/cell membrane biosynthesis, transport, signaling, DNA- and RNA-binding activities and protein synthesis. Importantly, while there are similarities and differences among gene categories that are regulated by fluconazole at the translational vs. transcriptional levels, we observe very little overlap among individual genes controlled by these mechanisms. Our findings suggest that C. albicans possesses distinct translational mechanisms that are important for the response to antifungal treatment, which could eventually be targeted by novel antifungal therapies.
 
Overall design Examination of gene expression by RNA-seq and Ribo-seq in 1 strain of Candida albicans grown under 2 conditions (YEPD + 1 ug/mL fluconazole at 30°C (Fluconazole)) and (YEPD + DMSO vehicle only control at 30°C (No drug)). There are four biological replicates for each strain grown under each condition (16 samples total).
 
Contributor(s) Kadosh D, Choudhary S
Citation(s) 37610232
Submission date Mar 17, 2023
Last update date Oct 26, 2023
Contact name David Kadosh
E-mail(s) kadosh@uthscsa.edu
Phone (210) 567-3976
Organization name University of Texas Health Science Center at San Antonio
Department Department of Microbiology, Immunology & Molecular Genetics
Street address 7703 Floyd Curl Dr., MC: 7758
City San Antonio
State/province Texas
ZIP/Postal code 78229
Country USA
 
Platforms (1)
GPL27827 Illumina HiSeq 3000 (Candida albicans)
Samples (16)
GSM7103604 fluconazole-ribo-1
GSM7103605 fluconazole-ribo-2
GSM7103606 fluconazole-ribo-3
Relations
BioProject PRJNA945876

Download family Format
SOFT formatted family file(s) SOFTHelp
MINiML formatted family file(s) MINiMLHelp
Series Matrix File(s) TXTHelp

Supplementary file Size Download File type/resource
GSE227590_ribo_rna_counts.tsv.gz 182.7 Kb (ftp)(http) TSV
SRA Run SelectorHelp
Raw data are available in SRA
Processed data are available on Series record

| NLM | NIH | GEO Help | Disclaimer | Accessibility |
NCBI Home NCBI Search NCBI SiteMap